Fig. 4: NETs upregulated TF expression in endothelial cells through activation of the STING pathway.

A Western blot images of the STING activation in HUVECs. B Relative mRNA levels of the STING activation in HUVECs (n = 3). C Representative images of immunofluorescence staining of STING in HUVECs. Scale bar: 100 μm. D Representative optical images of control and NET-treated HUVECs with or without the STING inhibitor H-151. Scale bar: 100 μm. E The cell viability of HUVECs with different treatments using the CCK-8 assay (n = 4). F Western blot images of p-STING and TF expression in HUVECs with different treatments. G Relative mRNA levels of STING and TF in HUVECs with different treatments (n = 4). H Relative mRNA levels of STING in HUVECs transfected with LV-negative control (NC) or LV-STING (n = 3). I Western blot images of STING expression in HUVECs transfected with LV-NC or LV-STING. J Western blot images of STING and TF expression in NET-treated HUVECs transfected with LV-NC or LV-STING. Each bar represents the mean ± SD. The comparison between the two groups was performed using unpaired t-tests (A, B, and H). Statistical analysis for three or more groups was carried out using 1-way ANOVA (E and G). *p < 0.05, **p < 0.01, ***p < 0.001.